Bacil Pharma P/E Ratio
Current P/E Ratio
111.76
High Valuation
Very High - High growth expectations or significantly overvalued
Bacil Pharma (BACPHAR) P/E ratio is 111.76 (High), EPS (TTM) ₹0.64, current price ₹53.78 on BSE — Very High - High growth expectations or significantly overvalued. Browse BACPHAR complete financial statements for revenue, profit, balance sheet and cash flow data.
Current Valuation Metrics
P/E Ratio
111.76
Current Price
₹53.78
EPS (TTM)
₹0.64
Exchange
BSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
49.56
Sector Median
29.34
Sector Rank
#11 of 190
Sector Percentile
5.8%
BACPHAR P/E Ratio — Valuation Signal & Historical Context
Bacil Pharma P/E 111.76 — signal: Overvalued. For live price, revenue and the complete fundamental profile, see Bacil Pharma share price screener.
- Stock appears overvalued with PE of 111.76, suggesting caution for new investments
- Trading at premium to sector average PE of 49.56
BACPHAR vs Healthcare Peers — P/E Ratio Comparison
Bacil Pharma P/E 111.76 vs Healthcare average 49.56, median 29.34 — range 1.0–869.57.
Sector Average
49.56
Sector Median
29.34
Lowest P/E
1.0
Highest P/E
869.57
Companies
190
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Welcure Drugs & Pharmace… | WELCURE | 1.0 | ₹36 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.45 | ₹61 | Low |
| Ind Swift Laboratories | INDSWFTLAB | 4.69 | ₹1,161 | Low |
| Amwill Health Care | AMWILL | 6.34 | ₹65 | Low |
| Brooks Laboratories | BROOKS | 6.6 | ₹137 | Low |
| Mono Pharmacare | MONOPHARMA | 7.1 | ₹21 | Low |
| Shelter Pharma | SHELTER | 7.4 | ₹54 | Low |
| Medicamen Organics | MEDIORG | 7.51 | ₹32 | Low |
| Zenith Drugs | ZENITHDRUG | 7.69 | ₹66 | Low |